ClinicalTrials.gg
CompletedNCT03799978Updated Apr 12, 2019

A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects

A Phase 1 interventional study of ACT-541468 in Healthy, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Czechia. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-12.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2019, 7 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is a single-center, open-label, randomized, two way crossover study to investigate the food effect on the pharmacokinetics of ACT-541468 in healthy male subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to any study-mandated procedure
  • Healthy male subjects aged between 18 and 45 years (inclusive) at Screening
  • (BMI) of 18.0 to 28.0 kg/m2 (inclusive) at Screening
  • No findings on the physical examination at Screening

Exclusion criteria

Exclusion Criteria:

  • History of major medical or surgical disorders, which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatments (appendectomy and herniotomy allowed, cholecystectomy not allowed)
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
  • Modified Swiss Narcolepsy Scale total score \< 0 at screening or history of narcolepsy or cataplexy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment A: ACT-541468 50 mg under fasted conditions

    Single oral dose administered on Day 1 under fasted conditions.

    Drug: ACT-541468

  • Experimental
    Treatment B: ACT-541468 50 mg under fed conditions

    Single oral dose administered on Day 1 administered after food intake.

    Drug: ACT-541468

Interventions

  • ACT-541468 50 mg film-coated tablets

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic endpoint: AUC0-24

    Area under the plasma concentration-time curve (AUC) from time zero to 24 h

    Time frame: Multiple timepoints; duration: up to 48 hours in each treatment period

Other outcomes

  1. Pharmacokinetic endpoint: AUC0-inf

    AUC from time zero to infinity

    Time frame: Multiple timepoints; duration: up to 48 hours in each treatment period

  2. Pharmacokinetic endpoint: Cmax

    Maximum plasma concentration

    Time frame: Multiple timepoints; duration: up to 48 hours in each treatment period

  3. Pharmacokinetic endpoint: tmax

    Time to reach maximum plasma concentration

    Time frame: Multiple timepoints; duration: up to 48 hours in each treatment period

  4. Pharmacokinetic endpoint: t½

    Terminal elimination half-life

    Time frame: Multiple timepoints; duration: up to 48 hours in each treatment period

  5. Treatment-emergent adverse events

    Time frame: From study treatment administration up to EOT; duration: up to 48 hours in each treatment period

  6. Serious treatment-emergent adverse events

    Time frame: From study treatment administration up to EOT; duration: up to 48 hours in each treatment period

07

Study locations

1 site
  • CEPHA s.r.o.
    Pilsen, 323 00, Czechia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Mar 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2019
First posted
Jan 10, 2019
StartActual
Mar 9, 2019
Primary completionActual
Mar 18, 2019
CompletionActual
Mar 18, 2019
Last update
Apr 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03799978
Responsible party
Sponsor
First posted
Jan 10, 2019
Start date
Mar 9, 2019
Primary completion
Mar 18, 2019
Completion
Mar 18, 2019
Last update
Apr 12, 2019

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion